Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupEBOSF +15.85%77 Capex-to-Operating-Cash-Flow is 0.13 as of Jun. 2026, which is 50% below its 10-year median of 0.26. GuruFocus rates EBOSF with a GF Score™ of 77/100 and a GF Value™ of $43.69. The stock has 5 warning signs investors should review. Among 65 Medical Distribution companies, Ebos Group ranks better than 64.62% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Ebos Group (OTCPK:EBOSF) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Ebos Group Capex-to-Operating-Cash-Flow Related Terms
Ebos Group Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Ebos Group's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBOSF vs MCK, COR, CAH: Capex-to-Operating-Cash-Flow Comparison
For the Medical Distribution subindustry, Ebos Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Capex-to-Operating-Cash-Flow vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Ebos Group's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.13 mean?
Ebos Group (EBOSF) has a Capex-to-Operating-Cash-Flow of 0.13 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Ebos Group and its competitors. This is 50% below median its historical median of 0.26. Over the past decade, Ebos Group's Capex-to-Operating-Cash-Flow has ranged from 0.12 to 0.36. According to the industry distribution chart, Ebos Group ranks #23 out of 65 companies in the Medical Distribution industry, placing it in the top 35.4%.
Is Ebos Group's Capex-to-Operating-Cash-Flow too high?
Ebos Group's current Capex-to-Operating-Cash-Flow of 0.13 is 50% below median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.36. The Medical Distribution industry median Capex-to-Operating-Cash-Flow is 0.29. Ebos Group's value of 0.13 is 55.2% below this industry median. Based on the distribution chart, Ebos Group ranks #23 out of 65 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Capex-to-Operating-Cash-Flow compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #23 out of 65 companies for Capex-to-Operating-Cash-Flow. This puts Ebos Group in the upper half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.29. Ebos Group's value of 0.13 is 55.2% below this benchmark. Historically, Ebos Group's own Capex-to-Operating-Cash-Flow has ranged from 0.12 to 0.36 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 0.29, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Medical Distribution company?
The median Capex-to-Operating-Cash-Flow among Medical Distribution companies is 0.29, based on 65 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Capex-to-Operating-Cash-Flow of 0.13 is 55.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Capex-to-Operating-Cash-Flow is 0.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Capex-to-Operating-Cash-Flow is 0.13, which is 50% below median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current Capex-to-Operating-Cash-Flow of 0.13. The stock's GF Value™ is $43.69, compared to a current price of $23.75 — trading 45.6% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.13, which is 50% below median its 10-year median of 0.26 and 55.2% below the Medical Distribution industry median of 0.29. Ebos Group's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Ebos Group (EBOSF), the current Capex-to-Operating-Cash-Flow is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 45.6% below its estimated GF Value™ of $43.69.
Key valuation signals for EBOSF:
Capex-to-Operating-Cash-Flow: 0.13 (50% below median its 10-year median of 0.26)
GF Value™: $43.69 vs. price of $23.75 (45.6% below fair value)
Industry Position: 55.2% below the Medical Distribution median (#23 of 65)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for EBOSF
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
